Rigel Pharmaceuticals (FRA:RI2) Shiller PE Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:RI2 Rigel Pharmaceuticals Inc FRA:RI2
73 GF Score
Price €38.94
GF Value €23.72
! 10 Warning Signs
View Full Analysis

What is Rigel Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Rigel Pharmaceuticals  (FRA:RI2) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Rigel Pharmaceuticals Shiller PE Ratio Related Terms


Rigel Pharmaceuticals Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Rigel Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rigel Pharmaceuticals Shiller PE Ratio Chart

Rigel Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Rigel Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

FRA:RI2 vs FTH, SGP, ACRS: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Rigel Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rigel Pharmaceuticals Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Shiller PE Ratio falls into.


FRA:RI2
73GF Score
Rigel Pharmaceuticals Inc FRA:RI2
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rigel Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Rigel Pharmaceuticals's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Rigel Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.7599/333.9520*333.9520
=0.760

Current CPI (Jun. 2026) = 333.9520.

Rigel Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -2.151 241.428 -2.975
201612 -1.484 241.432 -2.052
201703 -1.220 243.801 -1.671
201706 -1.454 244.955 -1.982
201709 -1.193 246.819 -1.614
201712 -1.529 246.524 -2.071
201803 -1.383 249.554 -1.851
201806 -1.343 251.989 -1.780
201809 -1.228 252.439 -1.624
201812 0.169 251.233 0.224
201903 -0.927 254.202 -1.218
201906 -1.097 256.143 -1.430
201909 -0.617 256.759 -0.802
201912 -0.927 256.974 -1.204
202003 1.144 258.115 1.480
202006 -0.947 257.797 -1.226
202009 -0.718 260.280 -0.922
202012 -0.955 260.474 -1.224
202103 1.863 264.877 2.348
202106 -0.674 271.696 -0.829
202109 -1.040 274.310 -1.266
202112 -1.158 278.802 -1.387
202203 -1.424 287.504 -1.654
202206 -0.735 296.311 -0.829
202209 -1.093 296.808 -1.230
202212 0.080 296.797 0.090
202303 -0.727 301.836 -0.804
202306 -0.349 305.109 -0.382
202309 -0.300 307.789 -0.326
202312 0.039 306.746 0.043
202403 -0.434 312.332 -0.464
202406 -0.055 314.175 -0.058
202409 0.641 315.301 0.679
202412 0.748 315.605 0.791
202503 0.599 319.799 0.625
202506 2.896 322.561 2.998
202509 1.246 324.800 1.281
202512 11.635 324.054 11.991
202603 0.376 330.213 0.380
202606 0.760 333.952 0.760

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?

Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued. The current stock price of €38.94 is trading 64.2% above its estimated GF Value™ of €23.72.

Key valuation signals for FRA:RI2:

  • Shiller PE Ratio:
  • GF Value™: €23.72 vs. price of €38.94 (64.2% above fair value)
  • GF Score™: 73/100 with 10 warning signs

No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rigel Pharmaceuticals Business Description

Other Exchanges RIGL:USA
Address 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
73GF Score

Get the complete analysis for FRA:RI2

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€38.94
Price
€23.72
GF Value